Agios Pharmaceuticals (NASDAQ:AGIO) Insider Krishnan Viswanadhan Sells 2,959 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. This represents a 36.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $28.53 on Tuesday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm’s 50 day simple moving average is $28.08 and its 200-day simple moving average is $33.15. The company has a market cap of $1.67 billion, a P/E ratio of -4.01 and a beta of 0.89.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $25,000. First Horizon Corp purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth $45,000. Assetmark Inc. raised its holdings in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the first quarter valued at $40,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals during the fourth quarter valued at $49,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. HC Wainwright increased their target price on Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 12th. The Goldman Sachs Group lowered their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Finally, Royal Bank Of Canada lowered Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $57.00 to $28.00 in a research report on Wednesday, November 19th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.